We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Article |

Acute Myelocytic Leukemia

James F. Holland, MD; Oliver Glidewell, MA; Rose R. Ellison, MD; Robert W. Corey; Joel Schwartz, MD; H. James Wallace, MD; H. Clark Hoagland, MD; Peter Wiernik, MD; Kanti Rai, MD; J. George Bekesi, PhD; Janet Cuttner, MD
Arch Intern Med. 1976;136(12):1377-1381. doi:10.1001/archinte.1976.03630120029012.
Text Size: A A A
Published online


The difference between the chemotherapeutic response in patients with acute myelocytic leukemia (AML) and in those with acute lymphocytic leukemia (ALL) would appear to be more a problem of lack of regeneration of normal myeloid tissues than a lack of susceptibility of the neoplastic cell to chemotherapy. The lymphoblasts of ALL are more readily damaged by treatments used in induction than are the leukemic cells in AML. It is easily possible, however, to produce marrow aplasia in patients with AML with the multitude of myelosuppressive drugs available. The therapeutic dilemma is that treatments that are active in this regard also damage the normal myeloid tissue. This damage is often not repaired during the period available prior to death from infection or bleeding. The fact that differentiation between neoplastic and normal cells can be accomplished at all on chemotherapeutic grounds in such a critical organ as the marrow is remarkable. That


Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

First Page Preview

View Large
First page PDF preview





Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Some tools below are only available to our subscribers or users with an online account.

0 Citations

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.